Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 10.09% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.19 | 52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3442.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -161.01% | Return on Equity (TTM) -694.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5064418 | Price to Sales(TTM) - |
Enterprise Value -5064418 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 567456 | Shares Floating 428235 |
Shares Outstanding 567456 | Shares Floating 428235 | ||
Percent Insiders 8.84 | Percent Institutions 1.27 |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack Inc. (formerly known as Integrity Applications Inc.) was founded in 2000. It focuses on developing non-invasive glucose monitoring technology. The company has faced challenges in commercializing its product and achieving profitability.
Core Business Areas
- GlucoTrack: Development, manufacture, and commercialization of the GlucoTrack non-invasive glucose monitoring device. This includes the main GlucoTrack DF-F device, and related accessories and services.
Leadership and Structure
The company's leadership consists of the CEO, CFO, and a board of directors. Organizational structure includes departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- GlucoTrack DF-F: A non-invasive glucose monitoring device. This is the main product. Market share data is difficult to obtain due to the limited commercial success and small size of the company. Competitors include traditional blood glucose meters from companies like Dexcom (DXCM), Abbott (ABT), and Medtronic (MDT), as well as continuous glucose monitoring (CGM) systems.
Market Dynamics
Industry Overview
The glucose monitoring market is dominated by invasive blood glucose meters and continuous glucose monitoring systems. There is a growing demand for non-invasive solutions.
Positioning
GlucoTrack aims to differentiate itself with a non-invasive approach. However, it faces challenges in accuracy, reliability, and cost competitiveness compared to existing solutions.
Total Addressable Market (TAM)
The global diabetes care devices market is estimated to be worth tens of billions of dollars. GlucoTrack's positioning with respect to TAM is limited due to commercial challenges and a need for further validation of their technology.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential for improved patient comfort
- Addressable market need for non-invasive glucose monitoring
Weaknesses
- Limited commercial success
- Unproven accuracy and reliability compared to existing solutions
- High cost relative to traditional methods
- Small market share
- Dependence on capital infusions
Opportunities
- Partnerships with diabetes management companies
- Further technological advancements to improve accuracy
- Expansion into new markets
- Increased awareness and adoption of non-invasive monitoring
Threats
- Competition from established players in the glucose monitoring market
- Regulatory hurdles and approval processes
- Technological advancements in competing monitoring methods
- Lack of reimbursement from healthcare providers
Competitors and Market Share
Key Competitors
- DXCM
- ABT
- MDT
Competitive Landscape
GlucoTrack faces a highly competitive landscape dominated by established medical device companies with superior resources and market access. They must overcome barriers to accuracy, clinical validation, and cost-effectiveness to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to challenges in commercializing its product.
Future Projections: Future growth is uncertain and depends on technological advancements, regulatory approvals, and market adoption.
Recent Initiatives: Recent initiatives may include clinical trials, product enhancements, and strategic partnerships, but these are not readily available.
Summary
GlucoTrack is a small company attempting to penetrate a mature market dominated by invasive glucose monitoring systems. Their non-invasive approach is appealing, but they face challenges in proving clinical accuracy and achieving widespread market adoption. Financial performance has been weak. They will need significant partnerships and capital infusions to compete effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports (limited availability)
- Publicly available news and press releases
- OTC Markets data
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Accuracy is limited by the available data. The information is not guaranteed to be accurate or complete. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 11 | Website https://glucotrack.com |
Full time employees 11 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.